Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Validating the Lower-Risk MD Anderson Prognostic Scoring System (LR-PSS) and the Revised International Prognostic Scoring System (IPSS-R) for Patients with Myelodysplastic Syndromes

Mikkael A. Sekeres, MD, MS, Paul Elson, Ramon V. Tiu, MD, Yogen Saunthararajah, MD, Anjali S. Advani, MD, Katarina Paulic, Josephine Chan, Sherry Pierce, RN, BS, Elias Jabbour, Hagop M. Kantarjian, Jaroslaw P. Maciejewski, MD, PhD, Guillermo Garcia-Manero

Blood (2011) 118 (21): 1720.

https://doi.org/10.1182/blood.V118.21.1720.1720

Published: 2011

Journal Articles

High Rate of Survival in Transformed Lymphoma after Autologous Stem Cell Transplant (ASCT): Pathologic Analysis and Comparison with De Novo DLBCL.

Stephen S. Smith, MD, Brian Bolwell, MD, Anjali Advani, MD, Steven Andresen, DO, Josephine Chan, Robert Dean, MD, Eric Hsi, MD, Matt Kalaycio, MD, Brad Pohlman, MD, Lisa Rybicki, MS, Ronald Sobecks, MD, John Sweetenham, MD

Blood (2008) 112 (11): 1137.

https://doi.org/10.1182/blood.V112.11.1137.1137

Published: 2008

Journal Articles

Platelet Transfusion Requirement during ASCT for Lymphoma Is a Powerful Prognostic Variable.

Hien Duong, Lisa Rybicki, John Sweetenham, Brad Pohlman, Ronald Sobecks, Robert Dean, Edward Copelan, Steven Andresen, Stephen Smith, Shawnda Sungren, Josephine Chan, Brian Bolwell

Blood (2008) 112 (11): 3269.

https://doi.org/10.1182/blood.V112.11.3269.3269

Published: 2008

Journal Articles

Impact on Pulmonary Function of Pre-Transplant Radiotherapy in Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplant (ASCT).

Christy Stotler, DO, Paul Elson, ScD, Brian Bolwell, MD, Matt Kalaycio, MD, Brad Pohlman, MD, Ronald Sobecks, MD, Robert Dean, MD, Steven Andresen, DO, Edward Copelan, MD, Josephine Chan, John Sweetenham, MD

Blood (2008) 112 (11): 3279.

https://doi.org/10.1182/blood.V112.11.3279.3279

Published: 2008

Journal Articles

Fludarabine, but Not Mitoxantrone, Increases the Risk of a Poor Stem Cell Harvest and Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia (tMDS/AML) after Autologous Stem Cell Transplantation (ASCT) in Patients with Follicular Lymphoma (FL).

Jason Waterman, Lisa Rybicki, Brian Bolwell, Ronald Sobecks, Brad Pohlman, Edward Copelan, John Sweetenham, Robert Dean, Josephine Chan, Matt Kalaycio

Blood (2008) 112 (11): 2192.

https://doi.org/10.1182/blood.V112.11.2192.2192

Published: 2008

Journal Articles

Non-Relapse Mortality (NRM) after Autologous Stem Cell Transplant (ASCT) Is Reduced with Stringent Follow-up Post-Transplant.

Christy Stotler, DO, Lisa Rybicki, Matt Kalaycio, MD, Robert Dean, Edward A. Copelan, MD, Ronald Sobecks, MD, Brad Pohlman, MD, Steven Andresen, DO, John Sweetenham, MD, Kelly Cherni, RN, Josephine Chan, Brian J. Bolwell, MD

Blood (2008) 112 (11): 2155.

https://doi.org/10.1182/blood.V112.11.2155.2155

Published: 2008

Journal Articles

No Impact of Postremission Consolidation Chemotherapy Before Allogeneic Transplant in Patients with First Remission Acute Myeloid Leukemia with Intermediate or High Risk Cytogenetics.

Lisa O. Sproat, MD, MSW, Brian Bolwell, Lisa Rybicki, Matt Kalaycio, Robert Dean, Ronald Sobecks, Brad Pohlman, Steve Andresen, Shawnda Sungren, Josephine Chan, John Sweetenham, Ed Copelan

Blood (2008) 112 (11): 2164.

https://doi.org/10.1182/blood.V112.11.2164.2164

Published: 2008

Journal Articles

15 Year Follow-up of ABMT for NHL: Surprisingly Favorable Outcome for Younger Adults.

Hien Duong, Lisa Rybicki, Steven Andresen, Edward Copelan, Robert Dean, Matt Kalaycio, Brad Pohlman, Ronald Sobecks, John Sweetenham, Josephine Chan, Shawnda Sungren, Brian Bolwell

Blood (2008) 112 (11): 2183.

https://doi.org/10.1182/blood.V112.11.2183.2183

Published: 2008

Journal Articles

Comparison of 200 cGy vs. 400 cGy Total Body Irradiation (TBI) When Used with Fludarabine for Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation (RIC AHSCT).

Ronald Sobecks, Robert Dean, Lisa Rybicki, Josephine Chan, Karl Theil, Roger Macklis, Steve Andresen, Matt Kalaycio, Brad Pohlman, Christine Ferraro, Kelly Cherni, Laura Bernhard, John Sweetenham, Edward Copelan, Brian Bolwell

Blood (2007) 110 (11): 2003.

https://doi.org/10.1182/blood.V110.11.2003.2003

Published: 2007

Journal Articles

Pre-Transplant Hypogammaglobulinemia Influences Survival after Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT).

Ronald Sobecks, Matt Kalaycio, Lisa Rybicki, Josephine Chan, Robert Dean, Karen Sands, Mary Serafin, Jennifer Kosar, Steve Andresen, Brad Pohlman, Edward Copelan, Brian Bolwell

Blood (2007) 110 (11): 1979.

https://doi.org/10.1182/blood.V110.11.1979.1979

Published: 2007

Journal Articles

A Phase II Trial of Combination Therapy with Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients with Overlap Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) or Chronic Idiopathic Myelofibrosis (CIMF).

Mikkael A. Sekeres, MD, MS, Jaroslaw P. Maciejewski, MD, PhD, Matt Kalaycio, MD, Mary Laughlin, MD, PhD, Ronald Sobecks, MD, Anjali Advani, MD, Katarina Paulic, Josephine Chan, Alison Vellani, Azra Raza, MD

Blood (2007) 110 (11): 1457.

https://doi.org/10.1182/blood.V110.11.1457.1457

Published: 2007

Journal Articles

A Phase II Trial of Combination Therapy with Arsenic Trioxide (ATO) and Gemtuzumab Ozogamicin (GO) in Patients with High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) Arising from MDS.

Mikkael A. Sekeres, MD, MS, Jaroslaw P. Maciejewski, MD, PhD, Harry Paul Erba, MD, PhD, Ronald Sobecks, MD, Anjali Advani, MD, Julie Nichols, RN, Josephine Chan, PhD, Matt Kalaycio, MD

Blood (2006) 108 (11): 2669.

https://doi.org/10.1182/blood.V108.11.2669.2669

Published: 2006

Journal Articles

A Phase II Trial of Combination Therapy with Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients with Chronic Idiopathic Myelofibrosis (CIMF) or Overlap Myelodysplastic/Myeloproliferative Diseases (MDS/MPD).

Mikkael A. Sekeres, MD, MS, Jaroslaw P. Maciejewski, PhD, MD, Matt Kalaycio, MD, Julie Nichols, RN, Ronald Sobecks, MD, Anjali Advani, MD, Josephine Chan, PhD, Naomi Galili, Fatima Raza, Jessica Wasserman, Peter Westervelt, MD, Azra Raza, MD

Blood (2006) 108 (11): 4886.

https://doi.org/10.1182/blood.V108.11.4886.4886

Published: 2006

NARROW

Validating the Lower-Risk MD Anderson Prognostic Scoring System (LR-PSS) and the Revised International Prognostic Scoring System (IPSS-R) for Patients with Myelodysplastic Syndromes

High Rate of Survival in Transformed Lymphoma after Autologous Stem Cell Transplant (ASCT): Pathologic Analysis and Comparison with De Novo DLBCL.

Platelet Transfusion Requirement during ASCT for Lymphoma Is a Powerful Prognostic Variable.

Impact on Pulmonary Function of Pre-Transplant Radiotherapy in Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplant (ASCT).

Fludarabine, but Not Mitoxantrone, Increases the Risk of a Poor Stem Cell Harvest and Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia (tMDS/AML) after Autologous Stem Cell Transplantation (ASCT) in Patients with Follicular Lymphoma (FL).

Non-Relapse Mortality (NRM) after Autologous Stem Cell Transplant (ASCT) Is Reduced with Stringent Follow-up Post-Transplant.

No Impact of Postremission Consolidation Chemotherapy Before Allogeneic Transplant in Patients with First Remission Acute Myeloid Leukemia with Intermediate or High Risk Cytogenetics.

15 Year Follow-up of ABMT for NHL: Surprisingly Favorable Outcome for Younger Adults.

Comparison of 200 cGy vs. 400 cGy Total Body Irradiation (TBI) When Used with Fludarabine for Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation (RIC AHSCT).

Pre-Transplant Hypogammaglobulinemia Influences Survival after Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT).

A Phase II Trial of Combination Therapy with Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients with Overlap Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) or Chronic Idiopathic Myelofibrosis (CIMF).

A Phase II Trial of Combination Therapy with Arsenic Trioxide (ATO) and Gemtuzumab Ozogamicin (GO) in Patients with High-Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) Arising from MDS.

A Phase II Trial of Combination Therapy with Thalidomide, Arsenic Trioxide, Dexamethasone, and Ascorbic Acid (TADA) in Patients with Chronic Idiopathic Myelofibrosis (CIMF) or Overlap Myelodysplastic/Myeloproliferative Diseases (MDS/MPD).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only